Area 3

Hepatic oncology

Articles during the year 2015

Published originals: 13

Impact factor: mean: 13.24, total: 172.11

  • Liver imaging reporting and data system with MR Imaging: Evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US

    Darnell A, Forner A, Rimola J, Reig M, García-Criado Á, Ayuso C, Bruix J
    Radiology. 2015; 275: 698-707. IF: 6.867

  • Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer

    Barbier-Torres L, Delgado TC, García-Rodríguez JL, Zubiete-Franco I, Fernández-Ramos D, Buqué X, Cano A, Gutiérrez-de Juan V, Fernández-Domínguez I, Lopitz-Otsoa F, Fernández-Tussy P, Boix L, Bruix J, Villa E, Castro A, Lu SC, Aspichueta P, Xirodimas D, Varela-Rey M, Mato JM, Beraza N, Martínez-Chantar ML
    Oncotarget. 2015; 6(4): 2509-2523. IF: 6.359

  • Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

    Schulze K, Imbeaud S, Letouzé E Alexandrov L, Calderaro J,Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton M, Llovet JM, Zucman-Rossi J
    Nature Genetics. 2015; 47: 505-511. IF: 29.352

  • Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

    Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators
    Lancet Oncol. 2015; 16: 1344-1354. IF: 24.690

  • Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience

    de la Serna S, Vilana R, Sánchez-Cabús S, Calatayud D, Ferrer J, Molina V, Fondevila C, Bruix J, Fuster J, García-Valdecasas JC
    HPB (Oxford). 2015; 17: 387-393. IF: 2.675


Published editorials: 2

Impact factor: mean: 11.06, total: 22.11

  • Pattern of tumor progression in liver cancer: the missing partner in trial design

    Reig M, Bruix J
    Hepatology. 2015; 62: 674-676. IF: 11.055

  • Surgical resection for hepatocellular carcinoma: moving from what can be done to what is worth doing

    Romagnoli R, Mazzaferro V, Bruix J
    Hepatology. 2015; 62: 340-342. IF: 11.055

More articles